One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Grifols, S.A. (GRFS): score, valuation & FAQ
Grifols, S.A. (GRFS) is a Drug Manufacturers - General company that scores 71 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A) and PEG (A). On valuation, GRFS sits about 52% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -3% annual free-cash-flow growth over the next decade.
Is GRFS a good stock to buy?
Bull Rankings scores GRFS 71 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by P/E (A) and PEG (A). A score is a quantitative screen of Grifols, S.A.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does GRFS score 71 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). GRFS earns its highest marks on P/E (A) and PEG (A). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is GRFS overvalued or undervalued?
Based on $8.15, GRFS sits about 52% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -3% annual free-cash-flow growth over the next decade. It trades at a 10.9x× P/E (graded A). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in GRFS?
Net margin 3.0% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.